Astrazeneca Plc $AZN Position Raised by Foresight Global Investors Inc.

Foresight Global Investors Inc. raised its stake in Astrazeneca Plc (NYSE:AZN) by 19.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 290,672 shares of the company’s stock after acquiring an additional 47,495 shares during the period. Astrazeneca makes up 24.0% of Foresight Global Investors Inc.’s portfolio, making the stock its biggest position. Foresight Global Investors Inc.’s holdings in Astrazeneca were worth $51,013,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of AZN. Kestra Advisory Services LLC grew its holdings in shares of Astrazeneca by 4.0% during the fourth quarter. Kestra Advisory Services LLC now owns 100,607 shares of the company’s stock valued at $17,657,000 after buying an additional 3,911 shares during the last quarter. Transamerica Financial Advisors LLC raised its holdings in Astrazeneca by 15.2% in the 4th quarter. Transamerica Financial Advisors LLC now owns 4,982 shares of the company’s stock worth $874,000 after acquiring an additional 658 shares during the last quarter. Parkside Financial Bank & Trust lifted its position in Astrazeneca by 39.7% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,601 shares of the company’s stock valued at $281,000 after acquiring an additional 455 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its position in Astrazeneca by 104.1% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 2,486 shares of the company’s stock valued at $436,000 after acquiring an additional 1,268 shares in the last quarter. Finally, AlTi Global Inc. boosted its stake in Astrazeneca by 61.2% during the 4th quarter. AlTi Global Inc. now owns 6,467 shares of the company’s stock valued at $1,135,000 after purchasing an additional 2,455 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.

Astrazeneca Stock Down 1.9%

AZN stock opened at $178.79 on Friday. Astrazeneca Plc has a twelve month low of $137.23 and a twelve month high of $212.71. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The stock has a market cap of $277.28 billion, a P/E ratio of 26.85, a PEG ratio of 1.59 and a beta of 0.25. The business’s 50-day moving average price is $189.26 and its 200-day moving average price is $185.90.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The firm had revenue of $15.29 billion for the quarter, compared to analysts’ expectations of $14.93 billion. On average, equities research analysts forecast that Astrazeneca Plc will post 9.37 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently commented on AZN. DZ Bank raised Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. UBS Group restated a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Finally, Barclays reiterated a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.